The Impact of the Approval of Radium-223
Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Myrtle Beach, comments on the impact of the approval of radium-223 for bone metastases from prostate cancer.
Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Myrtle Beach, comments on the impact of the approval of radium-223 for bone metastases from prostate cancer.
Shore expects a remarkable new thought process regarding the treatment of bone metastases in relation to the drug's approval. In addition to the amelioration of pain and delay to the onset of radiation requirement for painful bone metastases, radium-223 also demonstrated delays to skeletal events (surgical intervention, cord compression).
Clinical Pearls
Radium-223 is unique, Shore says, in that it prolonged survival: The final analysis showed a 3.6-month improvement to overall survival.
- Shore anticipates a new thought process for the treatment of bone metastases from prostate cancer
- Radium-223 showed amelioration of pain, delay to the onset of radiation requirement for bone mets, and delays in skeletal events
- Radium-223 demonstrated a 3.6-month improvement to overall survival
<<<
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
